Grant: Alliance Grants
McMaster University
$153,685.00
Fully integrated biosensing platform-integrating blood/plasma separation, digital microfluidics, and electrochemistry
EF 2021-22
Résumé
Recently, there has been a great movement toward telemedicine and remote healthcare. Despite development of the digital infrastructure for remote consultation of patients with healthcare providers, there is a lack of bioanalytical technologies for at home use. These technologies analyze patient specimens for markers of health or disease. In the post-pandemic world of virtual consultations, there is a major opportunity for transformative bioanalytical technologies that can be used at the point-of-need. This is currently a 33-billion-dollar industry that is projected to experience double digit annual growths in the next five years.In this proposal, we will combine multiple innovative technologies, developed over decades of research at McMaster University and Verv Technologies, for the first time to solve the technological and scientific challenges involved in analyzing a drop of unprocessed blood for a panel of biomarkers at the point-of-need. McMaster University has developed a bio-barcode assay that uses DNA/antibody assemblies for specifically targeting biomarkers and releasing an electroactive DNA barcode for generating an electrical signal. This system is highly sensitive and specific and is amenable to analyzing multiple analytes at once. The assay currently works with undiluted plasma, requires long incubation steps, and is operated using a series of manual steps that is difficult to follow by a novice user. Verv technologies has developed a patented platform for assay automation that is designed to work directly with blood and small sample volumes to reduce assay time. Combining the two technologies, with support from this grant, is expected to overcome the major hurdles that have inhibited the translation of biosensors from the research lab to the market. The development of this unique technology in Canada, initially targeted to the monitoring of prostate cancer, will generate research and development and manufacturing jobs, and will positively contribute to Canada's medical technology landscape. Marketing such technology is critically important for delivering high quality healthcare in Canada and globally in a world moving to virtual care, and is expected to bring equity to the delivery of healthcare.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
570448-2021
Name nom
Soleymani, Leyla
Department département
Engineering Physics
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
153685
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1
Partie
1
Nb partie
2
Application title
Fully integrated biosensing platform-integrating blood/plasma separation, digital microfluidics, and electrochemistry
Keyword
NSERC
Application summary
Recently, there has been a great movement toward telemedicine and remote healthcare. Despite development of the digital infrastructure for remote consultation of patients with healthcare providers, there is a lack of bioanalytical technologies for at home use. These technologies analyze patient specimens for markers of health or disease. In the post-pandemic world of virtual consultations, there is a major opportunity for transformative bioanalytical technologies that can be used at the point-of-need. This is currently a 33-billion-dollar industry that is projected to experience double digit annual growths in the next five years.In this proposal, we will combine multiple innovative technologies, developed over decades of research at McMaster University and Verv Technologies, for the first time to solve the technological and scientific challenges involved in analyzing a drop of unprocessed blood for a panel of biomarkers at the point-of-need. McMaster University has developed a bio-barcode assay that uses DNA/antibody assemblies for specifically targeting biomarkers and releasing an electroactive DNA barcode for generating an electrical signal. This system is highly sensitive and specific and is amenable to analyzing multiple analytes at once. The assay currently works with undiluted plasma, requires long incubation steps, and is operated using a series of manual steps that is difficult to follow by a novice user. Verv technologies has developed a patented platform for assay automation that is designed to work directly with blood and small sample volumes to reduce assay time. Combining the two technologies, with support from this grant, is expected to overcome the major hurdles that have inhibited the translation of biosensors from the research lab to the market. The development of this unique technology in Canada, initially targeted to the monitoring of prostate cancer, will generate research and development and manufacturing jobs, and will positively contribute to Canada's medical technology landscape. Marketing such technology is critically important for delivering high quality healthcare in Canada and globally in a world moving to virtual care, and is expected to bring equity to the delivery of healthcare.